What are the reported outcomes of bronchial thermoplasty (BT) for the treatment of asthma?

Updated: Mar 30, 2021
  • Author: Said A Chaaban, MD; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print
Answer

Patients are expected to have respiratory-related adverse events such as cough, wheezing, and chest tightness during the treatment period. Most of these symptoms occur within 1 day of the procedure and resolve in an average of 7 days with standard therapy.

It is unclear why an intervention aiming at reduction of smooth-muscle mass would not affect FEV1. Given that the number of exacerbations is reduced with no change in FEV1, it may be that altered response to the inflammatory triggers plays a role in addition to the reduction in smooth-muscle mass. [10]

Outcomes from one randomized double-blind sham-controlled clinical trial showed significant reduction in severe asthma exacerbation, ED visits, and days missed out of work or school in the posttreatment period. [21]

Earlier studies did not assess efficacy and safety beyond 5 years. The BT10+ study, published in 2021, followed 192 patients (136 in the BT group and 56 in the control group) who had previously been enrolled in the AIR, RISA, and AIR2 studies with the aim of investigating the efficacy and safety of BT after 10 or more years. [38]  The primary efficacy endpoint was the durability of the treatment effect; the primary safety endpoint was the absence of clinically significant post-BT respiratory image changes. The investigators found that the efficacy of BT was sustained for 10 years or longer with an acceptable safety profile.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!